Learners that complete this webinar will be able to describe how proteomic biomarkers may be used to evaluate drug benefits and adverse effects during clinical development. This activity will examine evidence from multiple clinical trials and drug classes demonstrating the potential of proteomic measures to detect treatment effects earlier and with fewer participants than traditional clinical outcome studies and discuss their potential application in clinical research and drug development.